The massive authorized share increase without a concurrent business event (acquisition, financing, or restructuring) suggests the company is preparing for a large equity raise or stock-based transaction. Monitor for a follow-on offering, convertible note issuance, or acquisition announcement in the coming weeks.
Price Chart
Executive Summary
Ping An Biomedical Co., Ltd. filed its Fourth Amended and Restated Memorandum and Articles of Association, adopted by special resolution on 29 October 2026. The key change is a massive increase in authorized share capital from US$312,500 to US$12,500,000, with Class A shares rising from 122,500,000 to 4,900,000,000 and Class B shares from 2,500,000 to 100,000,000. This 40x capital expansion signals potential future dilution and a significant structural shift, though no immediate offering or business event is disclosed.
Key Facts
- Authorized share capital increased from US$312,500 to US$12,500,000 (40x increase).
- Class A ordinary shares authorized increased from 122,500,000 to 4,900,000,000.
- Class B ordinary shares authorized increased from 2,500,000 to 100,000,000.
- Par value remains US$0.0025 per share for both classes.
- Fourth Amended and Restated Memorandum and Articles adopted by Special Resolution on 29 October 2026.
- Prior Third Amended and Restated documents were adopted on 18 March 2026.
Financial Impact
Authorized share capital increased by US$12,187,500 (from US$312,500 to US$12,500,000), representing a 40x expansion in potential dilution capacity.
Risk Factors
- Potential massive dilution if the newly authorized shares are issued in a future offering.
- No disclosed use of proceeds or business rationale for the capital increase, creating uncertainty.
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-111735 |
| Document: ea030768201ex99-3.htm | 0001213900-26-111735 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+1 | — | — |
Oct 22, 2026 4d ago | 6-K | $4.76 $4.48 | ▲ +5.88% | ▲ +6.59% | $4.48 (+5.88%) |
Oct 22, 2026 4d ago | Press Release | $0.1340 $0.1190 | ▼ −11.19% | ▼ −10.67% | $4.48 (+3243.28%) |
Oct 21, 2026 5d ago | 6-K | $3.68 $5.40 | ▲ +46.85% | ▲ +48.03% | $4.48 (+21.74%) |
Sep 11, 2026 6w ago | 6-K | $0.1380 $0.1367 | ▲ +0.94% | ▲ +0.50% | $4.48 (−3146.38%) |
Jul 20, 2026 14w ago | 6-K | $0.1459 $0.1467 | ▲ +0.55% | ▼ −0.29% | $4.48 (+2970.60%) |
May 27, 2026 21w ago | 6-K | $0.1560 $0.1570 | ▼ −0.64% | ▼ −0.40% | $4.48 (−2771.79%) |
Feb 27, 2026 34w ago | EFFECT | $0.1490 $0.1430 | ▼ −4.03% | ▼ −4.08% | $4.48 (+2906.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers